WO1998048888A1 - Dual channel implantation neurostimulation techniques - Google Patents

Dual channel implantation neurostimulation techniques Download PDF

Info

Publication number
WO1998048888A1
WO1998048888A1 PCT/US1998/008613 US9808613W WO9848888A1 WO 1998048888 A1 WO1998048888 A1 WO 1998048888A1 US 9808613 W US9808613 W US 9808613W WO 9848888 A1 WO9848888 A1 WO 9848888A1
Authority
WO
WIPO (PCT)
Prior art keywords
locus
signals
electrode
tissue
induced
Prior art date
Application number
PCT/US1998/008613
Other languages
French (fr)
Inventor
Warren Starkebaum
Mark T. Rise
Marc T. Stein
Donald L. Hall
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to DE69836589T priority Critical patent/DE69836589T2/en
Priority to EP98919980A priority patent/EP1015070B1/en
Publication of WO1998048888A1 publication Critical patent/WO1998048888A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36146Control systems specified by the stimulation parameters
    • A61N1/3615Intensity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36146Control systems specified by the stimulation parameters
    • A61N1/36167Timing, e.g. stimulation onset
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36017External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Definitions

  • This invention relates to means of stimulating electrically excitable tissue, and more particularly relates to means for adjusting the locus at which action potentials are induced in such tissue.
  • SCS pain control
  • first and second electrodes are implanted adjacent the tissue to be stimulated.
  • a first electrical signal is applied to the first electrode and a second electrical signal is applied to the second electrode.
  • the frequency difference between the first and second signals is adjusted and the amplitudes of the first and second signals are adjusted such that the combined potentials induced in the locus by the first and second signals create action potentials in the locus, and the locus is altered.
  • the degree of surgical precision required for the implanting of the electrodes is reduced, because the locus at which the nerve fibers are stimulated can be adjusted by merely changing the frequency difference and amplitudes of the signals applied to the electrodes after the surgical procedure is completed.
  • the signals may be either sinusoidal or pulsed.
  • FIG. 1 is a diagrammatic view of a patient in which a preferred form of apparatus for spinal cord stimulation (SCS) made in accordance with the invention has been implanted;
  • SCS spinal cord stimulation
  • Figure 2 is a cross-sectional view of an exemplary spinal column showing a typical position at which electrodes made in accordance with the preferred practice of the invention have been implanted in the epidural space;
  • Figure 3 is a cross-sectional view like Figure 2 showing locus of potential changes induced in the spinal cord from a signal applied to a first one of two electrodes;
  • Figure 4 is a view like Figure 3 showing the locus of potential changes induced in the spinal cord from the application of a signal to the second of the electrodes;
  • Figure 5 is a view like Figure 4 showing the combined loci in the spinal cord at which potentials are induced from signals applied to the first and second electrodes;
  • Figure 6 is a view like Figure 5 showing the alteration of the loci due to increase in the amplitude of the signal applied to the first electrode and a decrease in amplitude of the signal applied to the second electrode;
  • Figure 7 is a view like Figure 6 showing the alteration of the loci due to an increase in amplitude of the signal applied to the second electrode and a decrease in amplitude of the signal applied to the first electrode;
  • Figure 8 is a timing diagram showing signals applied to the first and second electrodes illustrated in Figure 2 in relationship to the potentials induced in tissue adjacent the electrodes.
  • Figure 9 depicts an idealistic representation of the dual channel ITREL ("DO") version of the implantable pulse generator utilized in one of the preferred embodiments of the present invention.
  • Figure 10 shows the monolithic embodiment of switches Nl and N2 of Figure 9 along with the additional circuitry required to actuate or toggle each switch into the closed or open position.
  • Figure 11 is a schematic of the electrode switch utilized in each stimulating ("S"), recharging ("R”), and stimulating or recharging (“S or R”) switch depicted in Figure 9.
  • Figure 12 is a schematic of the circuit used to identify the most negative reference that is utilized as the AMP_OUT voltage level of Figure 9.
  • FIGS 13 and 14 illustrate the top level representation—along with the relevant control signals driving the electrode switches— of the output circuit depicted in Figure 9.
  • FIGS. 15-22 illustrate an alternative output circuit configuration for the implantable pulse generator. This alternative output circuit is called "transverse tripolar stimulation.” DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • a single electrical signal or pulse can cause depolarization near a cathode in electrically excitable tissue which includes neural tissue and muscle tissue.
  • Neural tissue includes peripheral nerves, the spinal cord surface, deep spinal cord tissue, deep brain tissue, and brain surface tissue.
  • Muscle tissue includes skeletal (red) muscle, smooth (white) muscle, and cardiac muscle.
  • a locus includes a set of points in three-dimensional space and refers to a volume of cells or parts of cells. Due to the electrical characteristics of both the three-dimensional volume conductor and the membrane properties, the potentials outside and inside a neuron respond to the depolarization, usually with exponential-type increases and then attenuation over time. The time constant for an isolated neuron membrane typically is 5-15 milliseconds (Nerve, Muscle and Synapse by Bernard Katz, circa 1972). For myelinated axons or muscle cells, it may be considerably shorter.
  • the local depolarization from a single pulse PI results in a transmembrane potential PT1 between times Tl and T3.
  • the peak of potential PT1 is below the transmembrane potential threshold TPT.
  • the pulse fails to produce an action potential in that cell.
  • Action potential is an all-or-none, nonlinear phenomenon, caused by opening of sodium gates, inrush of sodium of ions, and a delayed opening of potassium gates and a restoration of the membrane potential.
  • a certain amount of charge must be passed at the electrodes (amplitude [Volts] / resistance [Ohms] x pulse width [time]) in order to cause enough depolarization for an action potential to begin.
  • rheobase There is a certain minimum voltage needed, called rheobase, before an action potential can happen.
  • Electrode Basic neurophysiological principles, called “electrotonus”, show that in any volume of electrically excitable tissue in which two or more pulses, each of which alone is insufficient to bring the cells to threshold, arrive closely together in time, at least part of their effect is additive, i.e., the memory of the first pulse is still present when the second pulse arrives. If the sum of the potentials (distorted by resistive and capacitive properties of the surroundings and the cell membranes) can get some cells depolarized to threshold, then an action potential will start in those cells.
  • FIG. 8 is a schematic view of a patient 10 having an implant of a neurological stimulation system employing a preferred form of the present invention to stimulate spinal cord 12 of the patient.
  • the preferred system employs an implantable pulse generator 14 to produce a number of independent stimulation pulses which are sent to spinal cord 12 by insulated leads 16 and 18 coupled to the spinal cord by electrodes 16A and 18A ( Figure 2). Electrodes 16A and 18 A also can be attached to separate conductors included within a single lead.
  • implantable pulse generator 14 is either a modified ITREL II or a dual channel ITREL ("DO"). Both models of these implantable pulse generators are commercially available from Medtronic, Inc. and are capable of delivering multiple signals to the one or more electrodes on different channels.
  • the implantable pulse generator 14 can provide multiple signals at different adjustable frequencies, pulse widths, amplitudes, and repetition rates. However, in the DO implantable pulse generator 14, the repetition rates on the different channels are synchronized.
  • the detailed configuration of the output circuitry utilized in the DO implantable pulse generator 14 is shown in Figures 9-14.
  • the idealistic representation of the DO version of the implantable pulse generator 14 is depicted in Figure 9.
  • the pulse widths are digitally controlled by a timer.
  • the implantable pulse generator 14 must be able to generate different amplitudes while preventing unwanted cross-conduction from occurring between different electrode switches during stimulation.
  • only one of the channels of electrode switches are stimulated at any given time by the implantable pulse generator 14.
  • the programmed amplitude of the signal output of each channel of the DO implantable pulse generator 14 is stored across two different capacitors, C2 and C3. These capacitors C2 and C3 are commonly referenced to the same node AMP_OUT. Therefore, AMP1 and AMP2 represent the two amplitudes (voltages) that are stored across capacitors C2 and C3.
  • the 183 ohm resistor and switch 52 is used to discharge all or a portion of the charge on capacitors C2 and C3, thereby reducing the stored amplitude(s).
  • the switching regulator 50 is used to increase the charge, and thus amplitude, on capacitors C2 and C3.
  • switches Nl or N2 In order to use the electrodes (TPE) on channel 1 ("CHI”) or channel 2 ("CH2”) to stimulate the biological load or tissue "RL”, switches Nl or N2 must first be respectively opened or closed. After switch Nl or N2 is closed, the tissue "RL” is stimulated when the stimulating switches (designated “S”) or the stimulating/recharging switches (designated “S or R”) are closed. After the stimulation pulse is complete, the system then waits a finite period of time before producing a recharging pulse. In the preferred embodiment, the finite period of time is 244 ⁇ sec; however, a delay of 100 to 500 ⁇ sec. could be used.
  • the recharging switches (designated “R") or the “S or R” switches are closed in order to reverse the current through the tissue "RL", or in other words to recharge the tissue.
  • the reason for the finite period of time delay is to prevent the physiological cancellation of the stimulation effect.
  • the detailed circuit configuration of the "S", “R”, and “S or R” monolithic switches can be seen in Figure 11.
  • the capacitors 54 depicted in Figure 9 are used to maintain charge balance.
  • capacitors can be installed between the following terminal pairs in order to maintain charge balance: CPB1_1 - CPB1_2 and CPB2_1 - CPB2_2.
  • FIGS 15-22 illustrate an alternative output circuit configuration for the implantable pulse generator 14 called "transverse tripolar stimulation.”
  • This circuit configuration allows both channels to be utilized in order to simultaneously provide different amplitudes, frequencies, repetition rates, and pulse widths to three electrodes (one reference electrode and two electrodes at different amplitudes).
  • the system employs a programmer 20 which is coupled via a conductor 22 to a radio frequency antenna 24.
  • This system permits attending medical personnel to select the various signal output options—such as amplitude, pulse width, frequency, and repetition rate—after implant using radio frequency communications.
  • the preferred system employs fully implanted elements, systems employing partially implanted generators and radio-frequency coupling may also be used in the practice of the present invention (e.g., similar to products sold by Medtronic, Inc. under the trademarks X-trel and Mattrix).
  • Figure 2 is a cross-sectional view of spine 12 showing implantation of the distal end of insulated leads 16 and 18 which terminate in electrodes 16A and 18A within epidural space 26.
  • the electrodes may be conventional percutaneous electrodes, such as PISCES® model 3487A sold by Medtronic, Inc. Also shown is the subdural space 28 filled with cerebrospinal fluid (cfs), bony vertebral body 30, vertebral arch 31, and dura mater 32.
  • the spine also includes gray matter 34 and dorsal horns 36 and 37 and white matter, for example, dorsal columns 46 and dorsal lateral columns 47.
  • signal PI is applied to electrode 18A ( Figure 2) and signal P2 is applied to electrode 16A ( Figure 2).
  • signals PI and P2 are shown as pulses, they also may comprises sinusoidal signals. Pulses PI and P2 are generated at different frequencies. When the electric fields resulting from PI and P2 pass through the same point in space at different frequencies, there is a difference frequency electric field set up corresponding to the difference between the frequencies of the two signals. For example, if PI is generated at 150 Hz and P2 is generated at 50 Hz, the resulting difference frequency will be 100 Hz which is in the physiologic range.
  • Amplitude Al of PI is adjustable independently from amplitude A2 of P2.
  • the amplitude of the resulting difference frequency electric field is twice the amplitude of the individual electric fields.
  • line LI represents the edge of a three-dimensional locus LIA in which pulse PI applied to electrode 18A induces a potential PTl between times Tl and T3 that is less than the transmembrane potential threshold TPT for cells of interest in that locus.
  • line L2 represents the edge of another three-dimensional locus L2A in which the application of pulse P2 (Figure 8) to electrode 16A induces a depolarizing potential less than the transmembrane potential threshold TPT for cells of interest in that locus.
  • Figure 5 illustrates a locus L3A representing the intersection of loci LIA and L2A in which the combined potentials induced in locus L3 A from the difference frequency electric field produced by pulses PI and P2 creates an action potential in cells of interest in locus L3A as illustrated by potential PT3 in Figure 8.
  • the potential induced in locus LIA outside locus L3A is illustrated by potential PTl ( Figure 8).
  • line L4 represents the edge of another three-dimensional locus L4A resulting from the application of a pulse PI to electrode 18A having an amplitude greater than amplitude Al ( Figure 8), and line L5 represents the edge of another three-dimensional locus L5A resulting from the application of a pulse P2 to electrode 16A having an amplitude less than amplitude A2.
  • the intersection of loci L4A and L5A represents a locus L6A resulting from the difference frequency electric field produced by pulses PI and P2 in which action potentials are induced.
  • Locus L6A is moved mostly to the right relative to locus L3A shown in Figure 5. Action potentials are not induced outside locus L6A.
  • line L8 represents the edge of another three-dimensional locus L8A resulting from the application of a pulse P2 to electrode 16A having an amplitude greater than amplitude A2 ( Figure 8), and line L7 represents the edge of another three-dimensional locus L7A resulting from the application of a pulse PI to electrode 18A having an amplitude less than amplitude Al.
  • the intersection of loci L7A and L8A represents a locus L9A resulting from the difference frequency electric field produced by pulses PI and P2 in which action potentials are induced. It will be noted that the locus L9A is moved to the left compared with locus L3A shown in Figure 5. Action potentials are not induced outside locus L9A.
  • the ability to move the locus in which action potentials are induced is an important feature. In many therapies, it is important to prevent action potentials being induced in gray matter 34 or dorsal horns 36 and 37, dorsal roots 38 and 40, dorsal lateral columns 47 or peripheral nerves 42 and 44 in order to minimize the possibility of causing pain, motor effects, or uncomfortable paresthesia.
  • the locus in which action potentials are induced e.g., L3A, L6A or L9A

Abstract

A first electrical signal and a second electrical signal are transmitted to one or more implanted leads including first and second electrodes, respectively. The first and second signals have a difference in frequency such that the combined potentials induce action potentials in a certain locus of electrically excitable tissue. Means are provided for adjusting the frequency difference, as well as the amplitudes of the signals so that the locus is altered.

Description

DUAL CHANNEL IMPLANTATION NEUROSTIMULATION TECHNIQUES
BACKGROUND OF THE INVENTION Field of the Invention
This invention relates to means of stimulating electrically excitable tissue, and more particularly relates to means for adjusting the locus at which action potentials are induced in such tissue.
Description of the Related Art
Two major practical problems reduce the efficacy of epidural spinal cord stimulation
(SCS) for pain control. One is the difficulty of directing the stimulation-induced paresthesia to the desired body part and the other is the problem of disagreeable sensations or motor responses to the stimulation, which reduce the comfortable amplitude range of the stimulation. It is generally agreed that in SCS, for chronic pain, paresthesia should cover the whole pain region.
With present stimulation methods and equipment, only highly skilled and experienced practitioners are able to position a stimulation lead in such a way that the desired overlap is reached and desired results are obtained over time with minimal side effects. It requires much time and effort to focus the stimulation on the desired body region during surgery and, with single channel approaches, it is difficult to redirect it afterwards, even though some readjustments can be made by selecting a different contact combination, pulse rate, pulse width or voltage.
Redirecting paresthesia after surgery is highly desirable. Even if paresthesia covers the pain area perfectly during surgery, the required paresthesia pattern often changes later due to lead migration, or histological changes (such as the growth of connective tissue around the stimulation electrode) or disease progression. The problem of lead placement has been addressed by U.S. Patent No. 5,121,754 by the use of a lead with a deformable distal shape. These problems are not only found with SCS, but also with peripheral nerve stimulation (PNS), depth brain stimulation (DBS), cortical stimulation and also muscle or cardiac stimulation. A system capable of some adjustment of spinal cord excitation is described in PCT
International Publication No. WO 95/19804. However, that system requires three electrodes, optimally spaced, which is a serious handicap during the surgical procedure required in order to place these electrodes in the body. Three electrodes may require the use of a paddle arrangement which is surgically difficult to manipulate adjacent the spinal cord. In addition, that system has only limited adjustment capability, dependent on the distance from the electrodes to the spinal cord.
SUMMARY OF THE INVENTION
The present invention can be used to advantage for altering the locus in electrically excitable tissue at which action potentials are induced. According to a preferred embodiment, first and second electrodes are implanted adjacent the tissue to be stimulated. A first electrical signal is applied to the first electrode and a second electrical signal is applied to the second electrode. The frequency difference between the first and second signals is adjusted and the amplitudes of the first and second signals are adjusted such that the combined potentials induced in the locus by the first and second signals create action potentials in the locus, and the locus is altered.
By using the foregoing techniques, the degree of surgical precision required for the implanting of the electrodes is reduced, because the locus at which the nerve fibers are stimulated can be adjusted by merely changing the frequency difference and amplitudes of the signals applied to the electrodes after the surgical procedure is completed.
According to another embodiment of the invention, the signals may be either sinusoidal or pulsed.
BRIEF DESCRIPTION OF THE DRAWINGS These and other advantages and features of the invention will become apparent upon reading the following detailed description and referring to the accompanying drawings in which like numbers refer to like parts throughout and in which: Figure 1 is a diagrammatic view of a patient in which a preferred form of apparatus for spinal cord stimulation (SCS) made in accordance with the invention has been implanted;
Figure 2 is a cross-sectional view of an exemplary spinal column showing a typical position at which electrodes made in accordance with the preferred practice of the invention have been implanted in the epidural space; Figure 3 is a cross-sectional view like Figure 2 showing locus of potential changes induced in the spinal cord from a signal applied to a first one of two electrodes;
Figure 4 is a view like Figure 3 showing the locus of potential changes induced in the spinal cord from the application of a signal to the second of the electrodes;
Figure 5 is a view like Figure 4 showing the combined loci in the spinal cord at which potentials are induced from signals applied to the first and second electrodes;
Figure 6 is a view like Figure 5 showing the alteration of the loci due to increase in the amplitude of the signal applied to the first electrode and a decrease in amplitude of the signal applied to the second electrode;
Figure 7 is a view like Figure 6 showing the alteration of the loci due to an increase in amplitude of the signal applied to the second electrode and a decrease in amplitude of the signal applied to the first electrode; and
Figure 8 is a timing diagram showing signals applied to the first and second electrodes illustrated in Figure 2 in relationship to the potentials induced in tissue adjacent the electrodes.
Figure 9 depicts an idealistic representation of the dual channel ITREL ("DO") version of the implantable pulse generator utilized in one of the preferred embodiments of the present invention.
Figure 10 shows the monolithic embodiment of switches Nl and N2 of Figure 9 along with the additional circuitry required to actuate or toggle each switch into the closed or open position. Figure 11 is a schematic of the electrode switch utilized in each stimulating ("S"), recharging ("R"), and stimulating or recharging ("S or R") switch depicted in Figure 9.
Figure 12 is a schematic of the circuit used to identify the most negative reference that is utilized as the AMP_OUT voltage level of Figure 9.
Figures 13 and 14 illustrate the top level representation—along with the relevant control signals driving the electrode switches— of the output circuit depicted in Figure 9.
Figures 15-22 illustrate an alternative output circuit configuration for the implantable pulse generator. This alternative output circuit is called "transverse tripolar stimulation." DESCRIPTION OF THE PREFERRED EMBODIMENTS
Referring to Figure 8, a single electrical signal or pulse, such as PI, can cause depolarization near a cathode in electrically excitable tissue which includes neural tissue and muscle tissue. Neural tissue includes peripheral nerves, the spinal cord surface, deep spinal cord tissue, deep brain tissue, and brain surface tissue. Muscle tissue includes skeletal (red) muscle, smooth (white) muscle, and cardiac muscle. A locus includes a set of points in three-dimensional space and refers to a volume of cells or parts of cells. Due to the electrical characteristics of both the three-dimensional volume conductor and the membrane properties, the potentials outside and inside a neuron respond to the depolarization, usually with exponential-type increases and then attenuation over time. The time constant for an isolated neuron membrane typically is 5-15 milliseconds (Nerve, Muscle and Synapse by Bernard Katz, circa 1972). For myelinated axons or muscle cells, it may be considerably shorter.
As shown in Figure 8, the local depolarization from a single pulse PI results in a transmembrane potential PT1 between times Tl and T3. The peak of potential PT1 is below the transmembrane potential threshold TPT. As a result, the pulse fails to produce an action potential in that cell.
Action potential is an all-or-none, nonlinear phenomenon, caused by opening of sodium gates, inrush of sodium of ions, and a delayed opening of potassium gates and a restoration of the membrane potential. In general, a certain amount of charge must be passed at the electrodes (amplitude [Volts] / resistance [Ohms] x pulse width [time]) in order to cause enough depolarization for an action potential to begin. There is a reciprocal relationship between amplitude and pulse width: the product must reach a certain value before the threshold is reached. This relationship does not reach the Volts = 0 axis. There is a certain minimum voltage needed, called rheobase, before an action potential can happen. Basic neurophysiological principles, called "electrotonus", show that in any volume of electrically excitable tissue in which two or more pulses, each of which alone is insufficient to bring the cells to threshold, arrive closely together in time, at least part of their effect is additive, i.e., the memory of the first pulse is still present when the second pulse arrives. If the sum of the potentials (distorted by resistive and capacitive properties of the surroundings and the cell membranes) can get some cells depolarized to threshold, then an action potential will start in those cells.
Still referring to Figure 8, the inducement of an action potential in a cell is illustrated by a transmembrane depolarizing potential PT3 reaching the transmembrane potential threshold TPT at time T4. Figure 1 is a schematic view of a patient 10 having an implant of a neurological stimulation system employing a preferred form of the present invention to stimulate spinal cord 12 of the patient. The preferred system employs an implantable pulse generator 14 to produce a number of independent stimulation pulses which are sent to spinal cord 12 by insulated leads 16 and 18 coupled to the spinal cord by electrodes 16A and 18A (Figure 2). Electrodes 16A and 18 A also can be attached to separate conductors included within a single lead.
In the preferred embodiment, implantable pulse generator 14 is either a modified ITREL II or a dual channel ITREL ("DO"). Both models of these implantable pulse generators are commercially available from Medtronic, Inc. and are capable of delivering multiple signals to the one or more electrodes on different channels. The implantable pulse generator 14 can provide multiple signals at different adjustable frequencies, pulse widths, amplitudes, and repetition rates. However, in the DO implantable pulse generator 14, the repetition rates on the different channels are synchronized. The detailed configuration of the output circuitry utilized in the DO implantable pulse generator 14 is shown in Figures 9-14.
The idealistic representation of the DO version of the implantable pulse generator 14 is depicted in Figure 9. In this version of the implantable pulse generator 14, the pulse widths are digitally controlled by a timer. The implantable pulse generator 14 must be able to generate different amplitudes while preventing unwanted cross-conduction from occurring between different electrode switches during stimulation. In this version of the implantable pulse generator 14, only one of the channels of electrode switches are stimulated at any given time by the implantable pulse generator 14.
The programmed amplitude of the signal output of each channel of the DO implantable pulse generator 14 is stored across two different capacitors, C2 and C3. These capacitors C2 and C3 are commonly referenced to the same node AMP_OUT. Therefore, AMP1 and AMP2 represent the two amplitudes (voltages) that are stored across capacitors C2 and C3. The 183 ohm resistor and switch 52 is used to discharge all or a portion of the charge on capacitors C2 and C3, thereby reducing the stored amplitude(s). Similarly, the switching regulator 50 is used to increase the charge, and thus amplitude, on capacitors C2 and C3.
Thus, in order to use the electrodes (TPE) on channel 1 ("CHI") or channel 2 ("CH2") to stimulate the biological load or tissue "RL", switches Nl or N2 must first be respectively opened or closed. After switch Nl or N2 is closed, the tissue "RL" is stimulated when the stimulating switches (designated "S") or the stimulating/recharging switches (designated "S or R") are closed. After the stimulation pulse is complete, the system then waits a finite period of time before producing a recharging pulse. In the preferred embodiment, the finite period of time is 244μsec; however, a delay of 100 to 500 μsec. could be used. After the finite period of time elapses, the recharging switches (designated "R") or the "S or R" switches are closed in order to reverse the current through the tissue "RL", or in other words to recharge the tissue. The reason for the finite period of time delay is to prevent the physiological cancellation of the stimulation effect. The detailed circuit configuration of the "S", "R", and "S or R" monolithic switches can be seen in Figure 11. Other than capacitors C2 and C3, the capacitors 54 depicted in Figure 9 are used to maintain charge balance. Similarly, capacitors can be installed between the following terminal pairs in order to maintain charge balance: CPB1_1 - CPB1_2 and CPB2_1 - CPB2_2.
As previously mentioned, Figures 15-22 illustrate an alternative output circuit configuration for the implantable pulse generator 14 called "transverse tripolar stimulation." This circuit configuration allows both channels to be utilized in order to simultaneously provide different amplitudes, frequencies, repetition rates, and pulse widths to three electrodes (one reference electrode and two electrodes at different amplitudes).
In the preferred embodiment of the present invention, the system employs a programmer 20 which is coupled via a conductor 22 to a radio frequency antenna 24. This system permits attending medical personnel to select the various signal output options— such as amplitude, pulse width, frequency, and repetition rate—after implant using radio frequency communications. While the preferred system employs fully implanted elements, systems employing partially implanted generators and radio-frequency coupling may also be used in the practice of the present invention (e.g., similar to products sold by Medtronic, Inc. under the trademarks X-trel and Mattrix). Figure 2 is a cross-sectional view of spine 12 showing implantation of the distal end of insulated leads 16 and 18 which terminate in electrodes 16A and 18A within epidural space 26. The electrodes may be conventional percutaneous electrodes, such as PISCES® model 3487A sold by Medtronic, Inc. Also shown is the subdural space 28 filled with cerebrospinal fluid (cfs), bony vertebral body 30, vertebral arch 31, and dura mater 32. The spine also includes gray matter 34 and dorsal horns 36 and 37 and white matter, for example, dorsal columns 46 and dorsal lateral columns 47.
Referring to Figure 8, signal PI is applied to electrode 18A (Figure 2) and signal P2 is applied to electrode 16A (Figure 2). Although signals PI and P2 are shown as pulses, they also may comprises sinusoidal signals. Pulses PI and P2 are generated at different frequencies. When the electric fields resulting from PI and P2 pass through the same point in space at different frequencies, there is a difference frequency electric field set up corresponding to the difference between the frequencies of the two signals. For example, if PI is generated at 150 Hz and P2 is generated at 50 Hz, the resulting difference frequency will be 100 Hz which is in the physiologic range.
Amplitude Al of PI is adjustable independently from amplitude A2 of P2. For the case in which amplitudes Al and A2 are equal, the amplitude of the resulting difference frequency electric field is twice the amplitude of the individual electric fields.
Referring to Figure 3, line LI represents the edge of a three-dimensional locus LIA in which pulse PI applied to electrode 18A induces a potential PTl between times Tl and T3 that is less than the transmembrane potential threshold TPT for cells of interest in that locus.
Referring to Figure 4, line L2 represents the edge of another three-dimensional locus L2A in which the application of pulse P2 (Figure 8) to electrode 16A induces a depolarizing potential less than the transmembrane potential threshold TPT for cells of interest in that locus. Figure 5 illustrates a locus L3A representing the intersection of loci LIA and L2A in which the combined potentials induced in locus L3 A from the difference frequency electric field produced by pulses PI and P2 creates an action potential in cells of interest in locus L3A as illustrated by potential PT3 in Figure 8. The potential induced in locus LIA outside locus L3A is illustrated by potential PTl (Figure 8). Since PTl is lower than the transmembrane potential threshold TPT, there is no action potential created in locus LIA outside L3A. The potential created in locus in L2A outside L3A is illustrated by potential PT2 (Figure 8). Since potential PT2 is less than the transmembrane potential threshold TPT, there is no action potential created in locus L2A outside locus L3A.
Referring to Figure 6, line L4 represents the edge of another three-dimensional locus L4A resulting from the application of a pulse PI to electrode 18A having an amplitude greater than amplitude Al (Figure 8), and line L5 represents the edge of another three-dimensional locus L5A resulting from the application of a pulse P2 to electrode 16A having an amplitude less than amplitude A2. The intersection of loci L4A and L5A represents a locus L6A resulting from the difference frequency electric field produced by pulses PI and P2 in which action potentials are induced. Locus L6A is moved mostly to the right relative to locus L3A shown in Figure 5. Action potentials are not induced outside locus L6A.
Referring to Figure 7, line L8 represents the edge of another three-dimensional locus L8A resulting from the application of a pulse P2 to electrode 16A having an amplitude greater than amplitude A2 (Figure 8), and line L7 represents the edge of another three-dimensional locus L7A resulting from the application of a pulse PI to electrode 18A having an amplitude less than amplitude Al. The intersection of loci L7A and L8A represents a locus L9A resulting from the difference frequency electric field produced by pulses PI and P2 in which action potentials are induced. It will be noted that the locus L9A is moved to the left compared with locus L3A shown in Figure 5. Action potentials are not induced outside locus L9A. The ability to move the locus in which action potentials are induced is an important feature. In many therapies, it is important to prevent action potentials being induced in gray matter 34 or dorsal horns 36 and 37, dorsal roots 38 and 40, dorsal lateral columns 47 or peripheral nerves 42 and 44 in order to minimize the possibility of causing pain, motor effects, or uncomfortable paresthesia. In the described techniques, the locus in which action potentials are induced (e.g., L3A, L6A or L9A) can be manipulated to a desired area of the dorsal columns 46 without inducing action potentials in dorsal horns 36 and 37, gray matter 34 or dorsal lateral columns 47. Moreover, the ability to move the locus in which action potentials are induced drastically reduces the accuracy necessary for surgically implanting electrodes 16 A and 18 A, and may eliminate the need for surgical lead revisions. The foregoing techniques also may be applied to all electrically excitable tissue. Those skilled in the art will recognize that the preferred embodiments may be altered and amended without departing from the true spirit and scope of the appended claims.

Claims

We claim:
1. A system for altering the locus of electrically excitable tissue in which action potentials are induced comprising in combination: a first electrode adapted to be implanted adjacent said tissue; a second electrode adapted to be implanted adjacent said tissue; means for applying a first electrical signal having a first frequency and first amplitude to said first electrode and a second electrical signal having a second frequency and second amplitude to said second electrode, the frequency difference between said first frequency and said second frequency having a relationship such that the combined potentials induced in said locus by said first and second signals create action potentials in said locus; and means for adjusting said first and second frequencies and said first and second amplitudes so that said locus is altered.
2. A system, as claimed in claim 1, wherein said means for adjusting comprises means for making said first and second amplitudes substantially identical.
3. A system, as claimed in claim 1, wherein said first and second signals comprise sinusoidal signals.
4. A system, as claimed in claim 1, wherein said first and second signals comprise pulse signals.
5. A method for altering the locus of electrically excitable tissue in which action potentials are induced by means of first and second electrodes adapted to be implanted adjacent said tissue, said method comprising the steps of: applying a first electrical signal to said first electrode; applying a second electrical signals to said second electrode; adjusting the difference in frequency between said first and second signals; and adjusting the amplitudes of said first and second signals, such that the locus of the combined potentials induced by said first and second signals in which action potentials are created is altered, whereby the locus is positioned with respect to said tissue.
6. A method, as claimed in claim 5, wherein the step of adjusting said amplitudes comprises the step of making said amplitudes substantially identical.
7. A method, as claimed in claim 5, wherein said first and second signals comprise sinusoidal signals.
8. A method, as claimed in claim 5, wherein said first and second signals comprise pulse signals.
PCT/US1998/008613 1997-04-30 1998-04-29 Dual channel implantation neurostimulation techniques WO1998048888A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE69836589T DE69836589T2 (en) 1997-04-30 1998-04-29 IMPLANTABLE TWO-CHANNEL NEUROSTIMULATOR
EP98919980A EP1015070B1 (en) 1997-04-30 1998-04-29 Dual channel implantation neurostimulation techniques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/847,651 1997-04-30
US08/847,651 US5948007A (en) 1997-04-30 1997-04-30 Dual channel implantation neurostimulation techniques

Publications (1)

Publication Number Publication Date
WO1998048888A1 true WO1998048888A1 (en) 1998-11-05

Family

ID=25301159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008613 WO1998048888A1 (en) 1997-04-30 1998-04-29 Dual channel implantation neurostimulation techniques

Country Status (4)

Country Link
US (2) US5948007A (en)
EP (1) EP1015070B1 (en)
DE (1) DE69836589T2 (en)
WO (1) WO1998048888A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070518A3 (en) * 1999-07-19 2001-10-17 Sherwood Services AG Modulated high frequency tissue modification
WO2006135792A1 (en) * 2005-06-09 2006-12-21 Medtronic, Inc. Regional therapies for treatment of pain
US8845629B2 (en) 2002-04-08 2014-09-30 Medtronic Ardian Luxembourg S.A.R.L. Ultrasound apparatuses for thermally-induced renal neuromodulation
US8852163B2 (en) 2002-04-08 2014-10-07 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods
US8880186B2 (en) 2002-04-08 2014-11-04 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients with chronic heart failure
US8948865B2 (en) 2002-04-08 2015-02-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating heart arrhythmia
US9023037B2 (en) 2002-04-08 2015-05-05 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9072527B2 (en) 2002-04-08 2015-07-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatuses and methods for renal neuromodulation
US9108040B2 (en) 2004-10-05 2015-08-18 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9131978B2 (en) 2002-04-08 2015-09-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9192715B2 (en) 2002-04-08 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal nerve blocking
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9327122B2 (en) 2002-04-08 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9364280B2 (en) 2002-04-08 2016-06-14 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US9439726B2 (en) 2002-04-08 2016-09-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9474563B2 (en) 2002-04-08 2016-10-25 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9827040B2 (en) 2002-04-08 2017-11-28 Medtronic Adrian Luxembourg S.a.r.l. Methods and apparatus for intravascularly-induced neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10034708B2 (en) 2002-04-08 2018-07-31 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US10080864B2 (en) 2012-10-19 2018-09-25 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems, and methods
US10179020B2 (en) 2010-10-25 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10537385B2 (en) 2008-12-31 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility
US10874455B2 (en) 2012-03-08 2020-12-29 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US11338140B2 (en) 2012-03-08 2022-05-24 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5983141A (en) 1996-06-27 1999-11-09 Radionics, Inc. Method and apparatus for altering neural tissue function
US6161048A (en) 1997-06-26 2000-12-12 Radionics, Inc. Method and system for neural tissue modification
US7364577B2 (en) 2002-02-11 2008-04-29 Sherwood Services Ag Vessel sealing system
US7137980B2 (en) 1998-10-23 2006-11-21 Sherwood Services Ag Method and system for controlling output of RF medical generator
US7901400B2 (en) 1998-10-23 2011-03-08 Covidien Ag Method and system for controlling output of RF medical generator
US6516227B1 (en) 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
US20080033492A1 (en) * 2000-01-07 2008-02-07 Biowave Corporation Electro-therapy method
DK1246665T3 (en) 2000-01-07 2006-01-09 Biowave Corp Electromagnetic Therapy Device
US7013179B2 (en) * 2000-01-07 2006-03-14 Biowave Corporation Percutaneous electrode array
US6699242B2 (en) 2000-02-03 2004-03-02 Baylor College Of Medicine Methods and devices for intraosseous nerve ablation
US7024247B2 (en) * 2001-10-15 2006-04-04 Northstar Neuroscience, Inc. Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures
US7672730B2 (en) 2001-03-08 2010-03-02 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7831305B2 (en) 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US20040176831A1 (en) * 2000-07-13 2004-09-09 Gliner Bradford Evan Apparatuses and systems for applying electrical stimulation to a patient
US7756584B2 (en) 2000-07-13 2010-07-13 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7010351B2 (en) 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US20050021118A1 (en) * 2000-07-13 2005-01-27 Chris Genau Apparatuses and systems for applying electrical stimulation to a patient
US7236831B2 (en) * 2000-07-13 2007-06-26 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US6928320B2 (en) 2001-05-17 2005-08-09 Medtronic, Inc. Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US6606521B2 (en) 2001-07-09 2003-08-12 Neuropace, Inc. Implantable medical lead
WO2003026736A2 (en) * 2001-09-28 2003-04-03 Northstar Neuroscience, Inc. Methods and implantable apparatus for electrical therapy
JP2003201863A (en) * 2001-10-29 2003-07-18 Mitsubishi Heavy Ind Ltd Combustor and gas turbine with it
US7221981B2 (en) 2002-03-28 2007-05-22 Northstar Neuroscience, Inc. Electrode geometries for efficient neural stimulation
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US6978174B2 (en) * 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US6937891B2 (en) * 2002-04-26 2005-08-30 Medtronic, Inc. Independent therapy programs in an implantable medical device
US7089057B2 (en) * 2002-04-26 2006-08-08 Medtronic, Inc. Detection of possible failure of capacitive elements in an implantable medical device
ES2289307T3 (en) 2002-05-06 2008-02-01 Covidien Ag BLOOD DETECTOR TO CONTROL AN ELECTROCHIRURGICAL UNIT.
US20040049121A1 (en) * 2002-09-06 2004-03-11 Uri Yaron Positioning system for neurological procedures in the brain
US8613744B2 (en) 2002-09-30 2013-12-24 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
US8808284B2 (en) 2008-09-26 2014-08-19 Relievant Medsystems, Inc. Systems for navigating an instrument through bone
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US7236830B2 (en) 2002-12-10 2007-06-26 Northstar Neuroscience, Inc. Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders
US20050075680A1 (en) 2003-04-18 2005-04-07 Lowry David Warren Methods and systems for intracranial neurostimulation and/or sensing
US6959215B2 (en) 2002-12-09 2005-10-25 Northstar Neuroscience, Inc. Methods for treating essential tremor
US7044948B2 (en) 2002-12-10 2006-05-16 Sherwood Services Ag Circuit for controlling arc energy from an electrosurgical generator
WO2004064915A2 (en) 2003-01-22 2004-08-05 International Rehabilitative Sciences, Inc. Spinal cord stimulation with interferential current
CA2523540A1 (en) * 2003-04-24 2005-01-06 Northstar Neuroscience, Inc. Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation
EP1617776B1 (en) 2003-05-01 2015-09-02 Covidien AG System for programing and controlling an electrosurgical generator system
JP2007501067A (en) 2003-08-01 2007-01-25 ノーススター ニューロサイエンス インコーポレイテッド Apparatus and method for applying neural stimulation to patient
US8104956B2 (en) 2003-10-23 2012-01-31 Covidien Ag Thermocouple measurement circuit
EP2258294B1 (en) 2003-10-23 2013-01-09 Covidien AG Redundant temperature monitoring in electrosurgical systems for safety mitigation
US7396336B2 (en) 2003-10-30 2008-07-08 Sherwood Services Ag Switched resonant ultrasonic power amplifier system
US7131860B2 (en) 2003-11-20 2006-11-07 Sherwood Services Ag Connector systems for electrosurgical generator
US8060207B2 (en) 2003-12-22 2011-11-15 Boston Scientific Scimed, Inc. Method of intravascularly delivering stimulation leads into direct contact with tissue
US20050137646A1 (en) 2003-12-22 2005-06-23 Scimed Life Systems, Inc. Method of intravascularly delivering stimulation leads into brain
US7766905B2 (en) 2004-02-12 2010-08-03 Covidien Ag Method and system for continuity testing of medical electrodes
US7295875B2 (en) * 2004-02-20 2007-11-13 Boston Scientific Scimed, Inc. Method of stimulating/sensing brain with combination of intravascularly and non-vascularly delivered leads
US7780662B2 (en) 2004-03-02 2010-08-24 Covidien Ag Vessel sealing system using capacitive RF dielectric heating
US20050203600A1 (en) 2004-03-12 2005-09-15 Scimed Life Systems, Inc. Collapsible/expandable tubular electrode leads
US7177702B2 (en) 2004-03-12 2007-02-13 Scimed Life Systems, Inc. Collapsible/expandable electrode leads
US7590454B2 (en) 2004-03-12 2009-09-15 Boston Scientific Neuromodulation Corporation Modular stimulation lead network
US7231260B2 (en) 2004-05-06 2007-06-12 Boston Scientific Scimed, Inc. Intravascular self-anchoring electrode body with arcuate springs, spring loops, or arms
JP2008506464A (en) 2004-07-15 2008-03-06 ノーススター ニューロサイエンス インコーポレイテッド System and method for enhancing or influencing neural stimulation efficiency and / or efficacy
US7286879B2 (en) 2004-07-16 2007-10-23 Boston Scientific Scimed, Inc. Method of stimulating fastigium nucleus to treat neurological disorders
US20060052856A1 (en) 2004-09-08 2006-03-09 Kim Daniel H Stimulation components
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
US7628786B2 (en) 2004-10-13 2009-12-08 Covidien Ag Universal foot switch contact port
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US7565200B2 (en) 2004-11-12 2009-07-21 Advanced Neuromodulation Systems, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects
US7937160B2 (en) 2004-12-10 2011-05-03 Boston Scientific Neuromodulation Corporation Methods for delivering cortical electrode leads into patient's head
US8788044B2 (en) * 2005-01-21 2014-07-22 Michael Sasha John Systems and methods for tissue stimulation in medical treatment
US9474564B2 (en) 2005-03-31 2016-10-25 Covidien Ag Method and system for compensating for external impedance of an energy carrying component when controlling an electrosurgical generator
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US8929991B2 (en) 2005-10-19 2015-01-06 Advanced Neuromodulation Systems, Inc. Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits
US7729773B2 (en) 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
US7856264B2 (en) 2005-10-19 2010-12-21 Advanced Neuromodulation Systems, Inc. Systems and methods for patient interactive neural stimulation and/or chemical substance delivery
US8734438B2 (en) 2005-10-21 2014-05-27 Covidien Ag Circuit and method for reducing stored energy in an electrosurgical generator
US20070118198A1 (en) * 2005-11-07 2007-05-24 Prager Joshua P Neurostimulation lead with concentric electrodes
US7947039B2 (en) 2005-12-12 2011-05-24 Covidien Ag Laparoscopic apparatus for performing electrosurgical procedures
US20070142863A1 (en) 2005-12-15 2007-06-21 Kerry Bradley Apparatus and methods for stimulating tissue
US9186200B2 (en) 2006-01-24 2015-11-17 Covidien Ag System and method for tissue sealing
EP3210557B1 (en) 2006-01-24 2018-10-17 Covidien AG System for tissue sealing
US8216223B2 (en) 2006-01-24 2012-07-10 Covidien Ag System and method for tissue sealing
US7513896B2 (en) 2006-01-24 2009-04-07 Covidien Ag Dual synchro-resonant electrosurgical apparatus with bi-directional magnetic coupling
CA2574935A1 (en) 2006-01-24 2007-07-24 Sherwood Services Ag A method and system for controlling an output of a radio-frequency medical generator having an impedance based control algorithm
CA2574934C (en) 2006-01-24 2015-12-29 Sherwood Services Ag System and method for closed loop monitoring of monopolar electrosurgical apparatus
US8685016B2 (en) 2006-01-24 2014-04-01 Covidien Ag System and method for tissue sealing
US8147485B2 (en) 2006-01-24 2012-04-03 Covidien Ag System and method for tissue sealing
US7651493B2 (en) 2006-03-03 2010-01-26 Covidien Ag System and method for controlling electrosurgical snares
US7648499B2 (en) 2006-03-21 2010-01-19 Covidien Ag System and method for generating radio frequency energy
US7689289B2 (en) * 2006-03-22 2010-03-30 Medtronic, Inc. Technique for adjusting the locus of excitation of electrically excitable tissue with paired pulses
US7651492B2 (en) 2006-04-24 2010-01-26 Covidien Ag Arc based adaptive control system for an electrosurgical unit
US8753334B2 (en) 2006-05-10 2014-06-17 Covidien Ag System and method for reducing leakage current in an electrosurgical generator
US8034049B2 (en) 2006-08-08 2011-10-11 Covidien Ag System and method for measuring initial tissue impedance
US7731717B2 (en) 2006-08-08 2010-06-08 Covidien Ag System and method for controlling RF output during tissue sealing
US7769443B2 (en) * 2006-09-06 2010-08-03 Giancarlo Barolat Implantable reel for coiling an implantable elongated member
US7794457B2 (en) 2006-09-28 2010-09-14 Covidien Ag Transformer for RF voltage sensing
WO2008070189A2 (en) 2006-12-06 2008-06-12 The Cleveland Clinic Foundation Method and system for treating acute heart failure by neuromodulation
US9314618B2 (en) 2006-12-06 2016-04-19 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
JP2010512186A (en) 2006-12-06 2010-04-22 スパイナル・モデュレーション・インコーポレイテッド Hard tissue anchor and delivery device
CA2671286C (en) 2006-12-06 2017-09-19 Spinal Modulation, Inc. Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
US9427570B2 (en) 2006-12-06 2016-08-30 St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) Expandable stimulation leads and methods of use
US8554337B2 (en) * 2007-01-25 2013-10-08 Giancarlo Barolat Electrode paddle for neurostimulation
AU2008210504B2 (en) 2007-01-29 2012-07-26 Spinal Modulation, Inc. Sutureless lead retention features
US8549015B2 (en) 2007-05-01 2013-10-01 Giancarlo Barolat Method and system for distinguishing nociceptive pain from neuropathic pain
US8777941B2 (en) 2007-05-10 2014-07-15 Covidien Lp Adjustable impedance electrosurgical electrodes
GB0709834D0 (en) * 2007-05-22 2007-07-04 Gillbe Ivor S Array stimulator
US7834484B2 (en) 2007-07-16 2010-11-16 Tyco Healthcare Group Lp Connection cable and method for activating a voltage-controlled generator
AU2008282451B2 (en) 2007-07-27 2013-09-26 Second Sight Medical Products Implantable device for the brain
US8216220B2 (en) 2007-09-07 2012-07-10 Tyco Healthcare Group Lp System and method for transmission of combined data stream
US8512332B2 (en) 2007-09-21 2013-08-20 Covidien Lp Real-time arc control in electrosurgical generators
US8214057B2 (en) * 2007-10-16 2012-07-03 Giancarlo Barolat Surgically implantable electrodes
US8226639B2 (en) 2008-06-10 2012-07-24 Tyco Healthcare Group Lp System and method for output control of electrosurgical generator
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
CA2957010C (en) 2008-09-26 2017-07-04 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
WO2010062622A2 (en) 2008-10-27 2010-06-03 Spinal Modulation, Inc. Selective stimulation systems and signal parameters for medical conditions
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US8262652B2 (en) 2009-01-12 2012-09-11 Tyco Healthcare Group Lp Imaginary impedance process monitoring and intelligent shut-off
EP2411091A4 (en) 2009-03-24 2012-09-12 Spinal Modulation Inc Pain management with stimulation subthreshold to paresthesia
CA2761778A1 (en) 2009-05-15 2010-11-18 Spinal Modulation, Inc. Methods, systems and devices for neuromodulating spinal anatomy
US9463323B2 (en) * 2009-06-18 2016-10-11 Boston Scientific Neuromodulation Corporation Spatially selective nerve stimulation in high-frequency nerve conduction block and recruitment
WO2011143233A2 (en) 2010-05-10 2011-11-17 Spinal Modulation, Inc. Methods, systems and devices for reducing migration
US8788046B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
US8788048B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
US8788047B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
EP4201475A1 (en) 2011-01-03 2023-06-28 The Regents of the University of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
JP2014508581A (en) 2011-01-21 2014-04-10 カリフォルニア インスティテュート オブ テクノロジー Parylene-based microelectrode array implant for spinal cord stimulation
EP2670478B1 (en) 2011-02-02 2016-07-27 Spinal Modulation Inc. Devices and systemsfor the targeted treatment of movement disorders
WO2012129574A2 (en) 2011-03-24 2012-09-27 California Institute Of Technology Neurostimulator
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
BR112014011409A2 (en) 2011-11-11 2017-05-02 Neuroenabling Tech Inc noninvasive neuromodulation device to enable recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
AU2012334926B2 (en) 2011-11-11 2017-07-13 The Regents Of The University Of California Transcutaneous spinal cord stimulation: noninvasive tool for activation of locomotor circuitry
US20130165994A1 (en) * 2011-12-27 2013-06-27 David J. Ternes Maintaining stimulation therapy efficacy
WO2013101772A1 (en) 2011-12-30 2013-07-04 Relievant Medsystems, Inc. Systems and methods for treating back pain
EP2822641B1 (en) * 2012-03-08 2019-06-19 SPR Therapeutics, Inc. System for treatment of pain related to limb joint replacement surgery
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
CA2889478C (en) 2012-11-05 2020-11-24 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone and modulating nerves within the bone
EP3583979B1 (en) 2013-03-15 2021-04-28 Boston Scientific Neuromodulation Corporation Systems for delivering subthreshold therapy to a patient
AU2014228794B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
WO2014197564A1 (en) 2013-06-06 2014-12-11 Boston Scientific Neuromodulation Corporation System for delivering sub-threshold and super-threshold therapy
US9872719B2 (en) 2013-07-24 2018-01-23 Covidien Lp Systems and methods for generating electrosurgical energy using a multistage power converter
US9655670B2 (en) 2013-07-29 2017-05-23 Covidien Lp Systems and methods for measuring tissue impedance through an electrosurgical cable
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
WO2015048563A2 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
US20150217120A1 (en) 2014-01-13 2015-08-06 Mandheerej Nandra Neuromodulation systems and methods of using same
CN106456975B (en) 2014-05-22 2020-09-04 卡迪诺米克公司 Catheter and catheter system for electrical neuromodulation
WO2016029159A2 (en) 2014-08-21 2016-02-25 The Regents Of The University Of California Regulation of autonomic control of bladder voiding after a complete spinal cord injury
WO2016033369A1 (en) 2014-08-27 2016-03-03 The Regents Of The University Of California Multi-electrode array for spinal cord epidural stimulation
EP3194007B1 (en) 2014-09-08 2018-07-04 Cardionomic, Inc. Catheter and electrode systems for electrical neuromodulation
EP3194017A1 (en) 2014-09-08 2017-07-26 Cardionomic, Inc. Methods for electrical neuromodulation of the heart
EP3610917A1 (en) 2015-01-05 2020-02-19 Cardionomic, Inc. Cardiac modulation facilitation methods and systems
US11167139B2 (en) 2015-03-20 2021-11-09 Medtronic Sg, Llc Method and apparatus for multi modal electrical modulation of pain using composite electromagnetic fields
US10850102B2 (en) 2015-03-20 2020-12-01 Medtronic Sg, Llc Method and apparatus for multimodal electrical modulation of pain
US10434311B2 (en) 2015-03-20 2019-10-08 Stimgenics, Llc Method and apparatus for multimodal electrical modulation of pain
WO2017035512A1 (en) 2015-08-26 2017-03-02 The Regents Of The University Of California Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US11097122B2 (en) 2015-11-04 2021-08-24 The Regents Of The University Of California Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel
WO2017156039A1 (en) 2016-03-09 2017-09-14 CARDIONOMIC, Inc. Cardiac contractility neurostimulation systems and methods
US10780274B2 (en) 2016-08-22 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for delivering spinal cord stimulation therapy
US11540973B2 (en) 2016-10-21 2023-01-03 Spr Therapeutics, Llc Method and system of mechanical nerve stimulation for pain relief
EP3421081B1 (en) 2017-06-30 2020-04-15 GTX medical B.V. A system for neuromodulation
EP3664703A4 (en) 2017-09-13 2021-05-12 Cardionomic, Inc. Neurostimulation systems and methods for affecting cardiac contractility
JP2021535776A (en) 2018-08-13 2021-12-23 カーディオノミック,インク. Systems and methods that act on systole and / or relaxation
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
DE18205817T1 (en) 2018-11-13 2020-12-24 Gtx Medical B.V. SENSOR IN CLOTHING OF LIMBS OR FOOTWEAR
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
CN114040704A (en) 2019-05-06 2022-02-11 卡迪诺米克公司 System and method for denoising physiological signals during electrical neuromodulation
EP4027912A4 (en) 2019-09-12 2023-08-16 Relievant Medsystems, Inc. Systems and methods for tissue modulation
DE19211698T1 (en) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3774620A (en) * 1971-06-14 1973-11-27 Nemectron Gmbh Electromedicinal apparatus for interference current therapy
US3895639A (en) * 1971-09-07 1975-07-22 Rodler Ing Hans Apparatus for producing an interference signal at a selected location
US4071033A (en) * 1976-12-20 1978-01-31 Nawracaj Edward P Electrotherapeutic device with modulated dual signals
US5121754A (en) 1990-08-21 1992-06-16 Medtronic, Inc. Lateral displacement percutaneously inserted epidural lead
WO1995019804A1 (en) 1994-01-24 1995-07-27 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119792A (en) * 1978-03-03 1979-09-17 Iriyou Kougaku Kenkiyuushiyo K Electric stimulation device for removing pain
US4640286A (en) * 1984-11-02 1987-02-03 Staodynamics, Inc. Optimized nerve fiber stimulation
CA1279101C (en) * 1985-10-10 1991-01-15 Christopher Van Den Honert Multichannel electrical stimulator with improved channel isolation
US4813418A (en) * 1987-02-02 1989-03-21 Staodynamics, Inc. Nerve fiber stimulation using symmetrical biphasic waveform applied through plural equally active electrodes
US5117826A (en) * 1987-02-02 1992-06-02 Staodyn, Inc. Combined nerve fiber and body tissue stimulation apparatus and method
EP0293068A1 (en) * 1987-05-27 1988-11-30 Teijin Limited An electric therapeutic apparatus
GB8904998D0 (en) * 1989-03-04 1989-04-19 Matthews Tony Anaesthetising apparatus
US5522853A (en) * 1992-10-27 1996-06-04 Angeion Corporation Method and apparatus for progressive recruitment of cardiac fibrillation
US5913877A (en) * 1996-03-11 1999-06-22 Kroll; Mark W. Implantable defibrillator system for generating a biphasic waveform with enhanced phase transition
US5713922A (en) * 1996-04-25 1998-02-03 Medtronic, Inc. Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain
US5925070A (en) * 1996-04-04 1999-07-20 Medtronic, Inc. Techniques for adjusting the locus of excitation of electrically excitable tissue
US5690686A (en) * 1996-04-30 1997-11-25 Medtronic, Inc. Atrial defibrillation method
US5674266A (en) * 1996-06-27 1997-10-07 Survivalink Corporation Biphasic defibrillation isolation circuit and method
US5766226A (en) * 1996-12-09 1998-06-16 Angeion Corporation Switched discharge pathways for ICD having multiple output capacitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3774620A (en) * 1971-06-14 1973-11-27 Nemectron Gmbh Electromedicinal apparatus for interference current therapy
US3895639A (en) * 1971-09-07 1975-07-22 Rodler Ing Hans Apparatus for producing an interference signal at a selected location
US4071033A (en) * 1976-12-20 1978-01-31 Nawracaj Edward P Electrotherapeutic device with modulated dual signals
US5121754A (en) 1990-08-21 1992-06-16 Medtronic, Inc. Lateral displacement percutaneously inserted epidural lead
WO1995019804A1 (en) 1994-01-24 1995-07-27 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1015070A4

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070518A3 (en) * 1999-07-19 2001-10-17 Sherwood Services AG Modulated high frequency tissue modification
US9743983B2 (en) 2002-04-08 2017-08-29 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9474563B2 (en) 2002-04-08 2016-10-25 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US8845629B2 (en) 2002-04-08 2014-09-30 Medtronic Ardian Luxembourg S.A.R.L. Ultrasound apparatuses for thermally-induced renal neuromodulation
US8852163B2 (en) 2002-04-08 2014-10-07 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods
US8880186B2 (en) 2002-04-08 2014-11-04 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients with chronic heart failure
US8934978B2 (en) 2002-04-08 2015-01-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US8948865B2 (en) 2002-04-08 2015-02-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating heart arrhythmia
US8983595B2 (en) 2002-04-08 2015-03-17 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients with chronic heart failure
US8986294B2 (en) 2002-04-08 2015-03-24 Medtronic Ardian Luxembourg S.a.rl. Apparatuses for thermally-induced renal neuromodulation
US9023037B2 (en) 2002-04-08 2015-05-05 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9072527B2 (en) 2002-04-08 2015-07-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatuses and methods for renal neuromodulation
US9731132B2 (en) 2002-04-08 2017-08-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9125661B2 (en) 2002-04-08 2015-09-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9131978B2 (en) 2002-04-08 2015-09-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9138281B2 (en) 2002-04-08 2015-09-22 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation via catheter apparatuses having expandable baskets
US9186198B2 (en) 2002-04-08 2015-11-17 Medtronic Ardian Luxembourg S.A.R.L. Ultrasound apparatuses for thermally-induced renal neuromodulation and associated systems and methods
US9186213B2 (en) 2002-04-08 2015-11-17 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9192715B2 (en) 2002-04-08 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal nerve blocking
US9265558B2 (en) 2002-04-08 2016-02-23 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9289255B2 (en) 2002-04-08 2016-03-22 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9314630B2 (en) 2002-04-08 2016-04-19 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9320561B2 (en) 2002-04-08 2016-04-26 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9327122B2 (en) 2002-04-08 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9326817B2 (en) 2002-04-08 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating heart arrhythmia
US9364280B2 (en) 2002-04-08 2016-06-14 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US11033328B2 (en) 2002-04-08 2021-06-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9439726B2 (en) 2002-04-08 2016-09-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9445867B1 (en) 2002-04-08 2016-09-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation via catheters having expandable treatment members
US9456869B2 (en) 2002-04-08 2016-10-04 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9463066B2 (en) 2002-04-08 2016-10-11 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9468497B2 (en) 2002-04-08 2016-10-18 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9757192B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9486270B2 (en) 2002-04-08 2016-11-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9675413B2 (en) 2002-04-08 2017-06-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9707035B2 (en) 2002-04-08 2017-07-18 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10850091B2 (en) 2002-04-08 2020-12-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US10376311B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravascularly-induced neuromodulation
US10441356B2 (en) 2002-04-08 2019-10-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation via neuromodulatory agents
US9757193B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9814873B2 (en) 2002-04-08 2017-11-14 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US9827040B2 (en) 2002-04-08 2017-11-28 Medtronic Adrian Luxembourg S.a.r.l. Methods and apparatus for intravascularly-induced neuromodulation
US9827041B2 (en) 2002-04-08 2017-11-28 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatuses for renal denervation
US9895195B2 (en) 2002-04-08 2018-02-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9907611B2 (en) 2002-04-08 2018-03-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US10420606B2 (en) 2002-04-08 2019-09-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US9956410B2 (en) 2002-04-08 2018-05-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9968611B2 (en) 2002-04-08 2018-05-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US10376312B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for monopolar renal neuromodulation
US10034708B2 (en) 2002-04-08 2018-07-31 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US10039596B2 (en) 2002-04-08 2018-08-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatus for renal neuromodulation via an intra-to-extravascular approach
US10376516B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US10105180B2 (en) 2002-04-08 2018-10-23 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravascularly-induced neuromodulation
US10111707B2 (en) 2002-04-08 2018-10-30 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of human patients
US10124195B2 (en) 2002-04-08 2018-11-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US10130792B2 (en) 2002-04-08 2018-11-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs
US10293190B2 (en) 2002-04-08 2019-05-21 Medtronic Ardian Luxembourg S.A.R.L. Thermally-induced renal neuromodulation and associated systems and methods
US10179235B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US10179028B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating patients via renal neuromodulation
US10179027B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable baskets for renal neuromodulation and associated systems and methods
US10272246B2 (en) 2002-04-08 2019-04-30 Medtronic Adrian Luxembourg S.a.r.l Methods for extravascular renal neuromodulation
US10245429B2 (en) 2002-04-08 2019-04-02 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US10537734B2 (en) 2004-10-05 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9402992B2 (en) 2004-10-05 2016-08-02 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9108040B2 (en) 2004-10-05 2015-08-18 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9950161B2 (en) 2004-10-05 2018-04-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US7813803B2 (en) 2005-06-09 2010-10-12 Medtronic, Inc. Regional therapies for treatment of pain
WO2006135792A1 (en) * 2005-06-09 2006-12-21 Medtronic, Inc. Regional therapies for treatment of pain
US10537385B2 (en) 2008-12-31 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility
US10561460B2 (en) 2008-12-31 2020-02-18 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation systems and methods for treatment of sexual dysfunction
US10179020B2 (en) 2010-10-25 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US10874455B2 (en) 2012-03-08 2020-12-29 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US11338140B2 (en) 2012-03-08 2022-05-24 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US10080864B2 (en) 2012-10-19 2018-09-25 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems, and methods
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation

Also Published As

Publication number Publication date
EP1015070B1 (en) 2006-12-06
US6122548A (en) 2000-09-19
EP1015070A4 (en) 2004-05-06
EP1015070A1 (en) 2000-07-05
DE69836589T2 (en) 2007-09-27
US5948007A (en) 1999-09-07
DE69836589D1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
EP1015070B1 (en) Dual channel implantation neurostimulation techniques
US6083252A (en) Techniques for adjusting the locus of excitation of electrically excitable tissue
US7657318B2 (en) Technique for adjusting the locus of excitation of electrically excitable tissue
US7689289B2 (en) Technique for adjusting the locus of excitation of electrically excitable tissue with paired pulses
CA2180849C (en) Multichannel apparatus for epidural spinal cord stimulation
US9375575B2 (en) Short duration pre-pulsing to reduce stimulation-evoked side-effetcs
EP1446189B1 (en) Multiplexed electrode array extension
EP1868680B1 (en) Apparatus for detecting position and migration of neurostimulation leads
EP3132826A1 (en) Current steering for an implantable stimulator device involving fractionalized stimulation pulses
US20200147390A1 (en) Spinal Cord Stimulation for Dorsal Column Recruitment or Suppression Using Anodic and Cathodic Pulses
WO1997037721A1 (en) Techniques for adjusting the locus of excitation of electrically excitable tissue

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998919980

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998919980

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1998919980

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)